Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin

International Journal of Pharmaceutics

Volumn 476, Issue 1, 2014, Pages 169-177

  Liu, Ying ^a   Wang, Lan ^a   Zhao, Yiqing ^a   He, Man ^a   Zhang, Xin ^a   Niu, Mengmeng ^a   Feng, Nianping ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

In situ intestinal absorption In vitro lipolysis Oral bioavailability; Luteolin; Microemulsions; Nanostructured lipids carriers

Indexed keywords

LIPID; LUTEOLIN; NANOMATERIAL; DRUG CARRIER; EMULSION; WATER;

AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LIPOLYSIS; MALE; MICROEMULSION; NONHUMAN; PARTICLE SIZE; RAT; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; COMPARATIVE STUDY; EMULSION; ORAL DRUG ADMINISTRATION; SOLUBILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EMULSIONS; INTESTINAL ABSORPTION; LIPIDS; LUTEOLIN; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOSTRUCTURES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; WATER; X-RAY DIFFRACTION;

EID: 84907937390     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.09.052     Document Type: Article

References (40)

1. M.U. Anby, H.D. Williams, M. McIntosh, H. Benameur, G.A. Edwards, C.W. Pouton, and C.J.H. Porter Lipid digestion as a trigger for supersaturation: in vitro and in vivo evaluation of the utility of polymeric precipitation inhibitors in selfemulsifying drug delivery systems Mol. Pharm. 9 2012 2063 2079
2. T.L. Anne, S. Philip, and M. Anette In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems Int. J. Pharm. 417 2011 245 255
3. J.C. Bakala N'Goma, S. Amara, K. Dridi, V. Jannin, and F. Carriere Understanding lipid digestion in the GI tract for effective drug delivery Ther. Deliv. 3 2012 105 124
4. A. Beloqui, M. Solinís Á, A. Delgado, C. Evora, A. Isla, and A. Rodríguez-Gascón Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution J. Microencaps. 31 2014 1 8
5. J.Y. Bor, H.Y. Chen, and G.C. Yen Evaluation of antioxidant activity and inhibitory effect on nitric oxide production of some common vegetables J. Agric. Food Chem. 54 2006 1680 1686
6. T. Cershanik, and S. Benita Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs Eur. J. Pharm. Biopharm. 50 2000 179 188
7. H.Q. Chen, Z.U. Jin, X.J. Wang, X.M. Xu, L. Deng, and J.W. Zhao Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation Neurosci. Lett. 448 2008 175 179
8. P.P. Constantinides Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects Pharm. Res. 12 1995 1561 1572
9. A. Dahan, and A. Hoffman Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats Pharm. Res. 23 2006 2165 2174
10. A. Dahan, A. Hoffman, E. Touitou, and B.W. Barry Enhancement in Drug Delivery 2006 CRC Press 111 127
11. R. Devraj, H.D. Williams, D.B. Warren, K. Mohsin, C.J.H. Porter, and C.W. Pouton In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine Eur. J. Pharm. Sci. 49 2013 748 760
12. S. Doktorovová, J. Araújo, M.L. Garcia, E. Rakovský, and E.B. Souto Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC) Colloids Surf. B Biointerfaces 75 2010 538 542
13. G. Fricker, T. Kromp, A. Wendel, A. Blume, J. Zirkel, H. Rebmann, C. Setzer, R.O. Quinkert, C. Setzer, F. Martin, M.G. Christel, and C. Müller-Goymann Phospholipids and lipid-based formulations in oral drug delivery Pharm. Res. 27 2010 1469 1486
14. S. Günter, M. Irmgard, and M.S. Christoph Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin Planta Med. 74 2008 1667 1677
15. S. Hougee, A. Sanders, J. Faber, Y.M. Graus, W.B. Van den Berg, J. Garssen, H.F. Smit, and M.A. Hoijer Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages Biochem. Pharmacol. 69 2005 241 248
16. A.J. Humberstone, and W.N. Charman Lipid-based vehicles for the oral delivery of poorly water soluble drugs Adv. Drug. Deliv. Rev 25 1997 103 128
17. K. Jores, A. Haberland, S. Wartewig, K. Mäder, and W. Mehnert Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy Pharm. Res. 22 2005 1887 1897
18. S. Kayoko, S. Noriko, N. Ryushi, S. Motoyoshi, A. Izumi, N. Tsutomu, and K. Naohide Deglucuronidation of a flavonoid, luteolin monoglucuronide, during inflammation Drug Metab. Dispos. 29 2001 1521 1524
19. B. Koen, V. Ruth, V. Guido, and V.S. Johannes Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity J. Biol. Chem. 280 2005 5636 5645
20. H.W. Leunga, C.L. Kuob, W.H. Yangc, C.H. Lind, and H.Z. Lee Antioxidant enzymes activity involvement in luteolin-induced human lung squamous carcinoma CH27 cell apoptosis Eur. J. Pharmacol. 534 2006 12 18
21. Y. Liu, P.F. Wang, C. Sun, J.H. Zhao, Y. Du, F. Shi, and N.P. Feng Bioadhesion and enhanced bioavailability by wheat germ agglutinin-grafted lipid nanoparticles for oral delivery of poorly water-soluble drug bufalin Int. J. Pharm. 31 2011 260 265
22. Q.Z. Lu, A.H. Yu, and Y.W. Xi Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery Int. J. Pharm. 272 2009 191 198
23. Y. Lu, J.P. Qi, and W. Wu Absorption, distribution and pharmacokinetics of nanoemulsions Cur. Drug Metab. 13 2012 396 417
24. Y. Lu, K. Wu, L. Li, Y. He, L. Cui, N. Liang, and B. Mu Characterization and evaluation of an oral microemulsion containing the antitumor diterpenoid compound ent-11alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid Int. J. Nanomedicine 8 2013 1879 1886
25. P.C. Lv, H.Q. Li, J.Y. Xue, L. Shi, and H.L. Zhu Synthesis and biological evaluation of novel luteolin derivatives as antibacterial agents Eur. J. Med. Chem. 44 2009 908 914
26. H.L. Mu, H. Rene, and M. Anette Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate effects of digestion AAPS Pharm. Sci. Tech. 13 2013 637 646
27. R.H. Muller, M. Radtke, and S.A. Wissing Nanostructured lipid matrices for improved microencapsulation of drugs Int. J. Pharm. 242 2002 121 128
28. C. Olbrich, O. Kayser, and R.H. Muller Lipase degradation of Dynasan 114 and Dynasan 116 solid lipid nanoparticles (SLN) - effect of surfactants storage time and crystallinity Int. J. Pharm. 237 2002 119 128
29. L. Paula, K. Hanna, and L. Anni Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs Eur. J. Pharm. Biopharm. 78 2011 531 538
30. C.J.H. Porter, N.L. Trevaskis, and W.N. Charman Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discov. 6 2007 231 248
31. C.W. Pouton Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and self-microemulsifying drug delivery systems Eur. J. Pharm. Sci. 11 2000 93 98
32. J.P. Qi, Y. Lu, and W. Wu Absorption, distribution and pharmacokinetics of solid lipid nanoparticles Cur. Drug Metab. 13 2012 418 428
33. M. Radtke, E.B. Souro, and R.H. Muller Nanostructured lipid carriers:a novel generation of solid lipid drug carriers Pharm. Technol. Eur. 17 2005 45 50
34. R. Sane, R.K. Mittapalli, and W.F. Elmquist Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability J. Pharm. Sci. 102 2013 1343 1354
35. L. Sek, C.J. Porter, and W.N. Charman Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products by HPTLC coupled with in situ densitometric analysis Biomed. Anal. 25 2001 651 661
36. M. Shangguan, Y. Lu, J. Qi, J. Han, Z. Tian, Y. Xie, F. Hu, H. Yuan, and W. Wu Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin J. Biomater. Appl. 28 2014 887 896
37. N. Thomas, R. Holm, A. Mullertz, and T. Rades In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS) J. Control. Release 160 2012 25 32
38. Z.Q. Tian, J.P. Qi, Y. i, J. Han, X. Yuan H. l. Zhang, Y.C. Xie, F.Q. Hu, Y. Lu, and W. Wu Solidification of nanostructured lipid carrier (NLC) onto pellets by fluid-bed coating: preparation, in vitro characterization and bioavailability in dogs Powder Technol. 247 2013 120 127
39. H.D. Williams, N.L. Trevaskis, Y.Y. Yeap, M.U. Anby, C.W. Pouton, and C.J. Porter Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway Pharm. Res. 30 2013 2976 2992
40. W. Wu, Y. Wang, and L. Que Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system Eur. J. Pharm. Biopharm. 63 2006 288 294